Clinical trials: IDIOPATHIC PARKINSON'S DISEASE
Parkinson Disease
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations.
- Trial name
- NCT06553027
- Testing
- CVN424 75 mg, CVN424 150 mg
- Where
- 94 sites in United States, Australia and 7 more
- Volunteers
- 330 people
- Sponsor
- Cerevance
Parkinson's Disease
Trial of Extended Treatment With Liatermin (r-metHuGDNF) Administered by Continuous Intraputaminal (IPu)Infusion to Subjects With Idiopathic Parkinson's Disease Who Have Completed a Previous Trial of Liatermin
The purpose of this study is to determine long-term efficacy of continuous IPu liatermin infusion administered with concomitant standard anti-Parkinsonian therapy.
- Trial name
- NCT00111982
- Testing
- Liatermin
- Volunteers
- 34 people
- Sponsor
- Amgen
Advanced Idiopathic Parkinson's Disease
Sleep Efficiency Assessed by Polysomnography (PSG Sleep Lab Testing) in Advanced Parkinson's Disease
This is a phase 4 study to evaluate with Polysomnography (PSG) and subjective measures the effect of Rotigotine on sleep efficiency, maintenance, insomnia, nocturnal akinesia and night-time movement in bed, in patients with…
- Trial name
- REFRESH-PD (NCT01519882)
- Testing
- Rotigotine
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- UCB Pharma SA
Parkinson Disease
Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease
This study consists of two parts. Part A will evaluate the safety and tolerability of multiple doses of OXB-102 (AXO-Lenti-PD) in participants with Parkinson's disease.
- Trial name
- SUNRISE-PD (NCT03720418)
- Testing
- OXB-102, Imitation Surgical Procedure (ISP)
- Where
- 3 sites in France, United Kingdom
- Volunteers
- 6 people
- Sponsor
- Sio Gene Therapies
Tremor Associated With Tremor Dominant Parkinson's Disease
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease
The objectives of this study are to collect the long-term safety and effectiveness data of performing thalamotomy for tremor dominant Parkinson's Disease (TDPD) using the Exablate Neuro system.
- Trial name
- NCT04991831
- Testing
- Unilateral thalamotomy
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 50 people
- Sponsor
- InSightec
Idiopathic Parkinson's Disease
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
Parkinson's disease is a major neurodegenerative disorder in which there is a progressive loss of nigrostriatal dopaminergic neurons.
- Trial name
- MOTION (NCT00605683)
- Testing
- Safinamide (as add-on therapy)
- Where
- 125 sites in United States, Argentina and 18 more
- Volunteers
- 679 people
- Sponsor
- Newron Pharmaceuticals SPA
Parkinson's Disease
Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)
To determine the long-term safety and efficacy of a dose range of safinamide of 50-200 mg/day, p.o., compared to placebo, as add-on therapy in patients with early idiopathic Parkinson's disease who are currently receiving a…
- Trial name
- NCT00642889
- Testing
- Safinamide
- Volunteers
- 227 people
- Sponsor
- Newron Pharmaceuticals SPA
Idiopathic Parkinson's Disease
Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver Support
The study objective is to evaluate advantages and disadvantages of Neupro® versus oral anti-Parkinson medication by caregivers and physicians in idiopathic Parkinson's Disease patients requiring caregiver support in nursing home…
- Trial name
- CARE-ACT (NCT01330290)
- Testing
- Neupro®
- Where
- 54 sites in Germany
- Volunteers
- 148 people
- Sponsor
- UCB Pharma
Parkinson's Disease
The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease
To determine the effects of the NMDA antagonist, CP-101,606, in subjects with Parkinson's Disease
- Trial name
- NCT00163085
- Testing
- NR2B NMDA Antagonist CP-101,606 (traxoprodil)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Pfizer
IDIOPATHIC PARKINSON'S DISEASE
A Trial to Evaluate the Effects of Rotigotine Transdermal Patch on Early Morning Motor Impairment and Sleep Disorders Idiopathic Parkinson's Disease
The objective of this trial is to assess the effect of rotigotine (SPM 962) on the control of early morning motor impairment and sleep disorders in subjects with idiopathic PD.
- Trial name
- NCT00243945
- Testing
- Rotigotine
- Where
- Germany
- Volunteers
- 58 people
- Sponsor
- UCB Pharma
PD
A Clinical Study to Evaluate the Safety, and Tolerability of BBM-P002 in the Treatment of Parkinson's Disease
The purpose of the study is to evaluate the safety and tolerability of BBM-P002 for stereotactic injection to treat participants with idiopathic Parkinson's Disease (PD) during the dose-limiting toxicity (DLT) observation period.
- Trial name
- NCT07195825
- Testing
- Injecting BBM-P002 into the bilateral putamen
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Xinzhi BioMed Co., Ltd.
Parkinson's Disease
Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off
This study will evaluate the effects of immediate release (IR) carbidopa levodopa versus the effects of immediate-release carbidopa/levodopa on ERP parameters in patients with idiopathic PD.
- Trial name
- NCT00601978
- Testing
- carbidopa/levodopa, Carbidopa/Levodopa/Entacapone
- Sponsor
- Novartis Pharmaceuticals
Parkinson Disease
A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease.
This is a multi-center, randomized, double blind, adaptive, parallel-group, placebo controlled Phase 1b study to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamics of RO7486967 in participants with…
- Trial name
- NCT05924243
- Testing
- RO7486967
- Where
- 17 sites in United States, Netherlands and 1 more
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Parkinson Disease
Post Marketing Surveillance Study of Sifrol® in Patients With Idiopathic Parkinson's Disease
Study to document pramipexole dosing during monotherapy, occurrence of fluctuations and dyskinesias, dose increases after deterioration of Parkinson's disease (PD) symptoms, assessment of the reasons for add-on treatment with…
- Trial name
- NCT02248181
- Testing
- Pramipexole
- Volunteers
- 442 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Parkinson Disease
Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's
This is a first-in-human study to evaluate the safety and tolerability of repeat oral administrations of MRx0029 (20 participants) or MRx0005 (20 participants) in participants diagnosed with idiopathic PD.
- Trial name
- NCT05832775
- Testing
- MRx0029, MRx0005
- Sponsor
- 4D pharma plc
Parkinson's Disease
A Follow-up Study on Safety and Tolerability of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease
The purpose of this study is to document the long-term safety and tolerability after intracerebroventricular (ICV) administration of sNN0031 (PDGF-BB) in patients who participated in study sNN0031-001
- Trial name
- NCT01807338
- Where
- Sweden
- Volunteers
- 11 people
- Sponsor
- Newron Sweden AB
Parkinson Disease, Parkinson
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich…
- Conditions
- Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD)
- Trial name
- NEULARK (NCT06680830)
- Testing
- NEU-411
- Where
- 72 sites in United States, Israel and 4 more
- Volunteers
- 150 people
- Sponsor
- Neuron23 Inc.
Parkinson's Disease, Idiopathic
Study for the Early Diagnosis of Parkinson's Disease
The main objective of the study is to design and validate the blood based PDx gene expression and miRNA assay for the early diagnosis of Parkinson's disease patients.
- Trial name
- NCT02283073
- Where
- 6 sites in Israel, Italy
- Volunteers
- 410 people, healthy volunteers welcome
- Sponsor
- Bio Shai Ltd.
Parkinson Disease
A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa
This is a Phase III, multicentre, randomised, double-blind, placebo-controlled study to evaluate the effects of 100 mg safinamide, administered orally once daily (OD), in Chinese Parkinson's disease (PD) patients, experiencing…
- Trial name
- NCT03881371
- Testing
- Safinamide
- Where
- 31 sites in China
- Volunteers
- 307 people
- Sponsor
- Zambon SpA
Idiopathic Parkinson's Disease
Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms
The primary objective of this study was to demonstrate that Rotigotine improves non-motor symptoms compared to Placebo in subjects with Parkinson's Disease.
- Trial name
- NCT01300819
- Testing
- Rotigotine
- Where
- 87 sites in Austria, Belgium and 10 more
- Volunteers
- 349 people
- Sponsor
- UCB Pharma